Clinical Trials Browser

Phase 2/3 × OTHER × Cabergoline × Clear all

NCT01620138 2016-08-22

Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

Phase 2/3 Completed

21 enrolled 4 charts

Prolactinoma